دورية أكاديمية
أعرض في EDS

GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival.

التفاصيل البيبلوغرافية
العنوان: GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival.
المؤلفون: Petrusca DN; Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, 980 Walnut St., Indianapolis, IN 46202, USA., Mulcrone PL; Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, 980 Walnut St., Indianapolis, IN 46202, USA., Macar DA; Department of Biological Sciences, Duquesne University, 600 Forbes Ave., Pittsburgh, PA 15219, USA., Bishop RT; Department of Tumor Biology, H. Lee Moffitt Cancer Research Center and Institute, 12902 USF Magnolia Drive, Tampa, FL 33612, USA., Berdyshev E; Department of Medicine, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA., Suvannasankha A; Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, 980 Walnut St., Indianapolis, IN 46202, USA.; Richard L. Rodebush Veterans Affairs Medical Center, 1481 W 10th St., Indianapolis, IN 46202, USA., Anderson JL; Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, 980 Walnut St., Indianapolis, IN 46202, USA., Sun Q; Department of Medicine, Division of Hematology/Oncology, McGowan Institute for Regenerative Medicine, University of Pittsburgh, UPMC Hillman Cancer Center Research Pavilion, 5117 Centre Ave, Pittsburgh, PA 15213, USA., Auron PE; Department of Biological Sciences, Duquesne University, 600 Forbes Ave., Pittsburgh, PA 15219, USA., Galson DL; Department of Medicine, Division of Hematology/Oncology, McGowan Institute for Regenerative Medicine, University of Pittsburgh, UPMC Hillman Cancer Center Research Pavilion, 5117 Centre Ave, Pittsburgh, PA 15213, USA., Roodman GD; Department of Medicine, Hematology/Oncology Division, Indiana University School of Medicine, 980 Walnut St., Indianapolis, IN 46202, USA.; Richard L. Rodebush Veterans Affairs Medical Center, 1481 W 10th St., Indianapolis, IN 46202, USA.
المصدر: Cancers [Cancers (Basel)] 2022 Feb 02; Vol. 14 (3). Date of Electronic Publication: 2022 Feb 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Multiple myeloma (MM) remains incurable for most patients due to the emergence of drug resistant clones. Here we report a p53-independent mechanism responsible for Growth Factor Independence-1 (GFI1) support of MM cell survival by its modulation of sphingolipid metabolism to increase the sphingosine-1-phosphate (S1P) level regardless of the p53 status. We found that expression of enzymes that control S1P biosynthesis, SphK1 , dephosphorylation, and SGPP1 were differentially correlated with GFI1 levels in MM cells. We detected GFI1 occupancy on the SGGP1 gene in MM cells in a predicted enhancer region at the 5' end of intron 1, which correlated with decreased SGGP1 expression and increased S1P levels in GFI1 overexpressing cells, regardless of their p53 status. The high S1P:Ceramide intracellular ratio in MM cells protected c-Myc protein stability in a PP2A-dependent manner. The decreased MM viability by SphK1 inhibition was dependent on the induction of autophagy in both p53WT and p53mut MM. An autophagic blockade prevented GFI1 support for viability only in p53mut MM, demonstrating that GFI1 increases MM cell survival via both p53WT inhibition and upregulation of S1P independently. Therefore, GFI1 may be a key therapeutic target for all types of MM that may significantly benefit patients that are highly resistant to current therapies.
References: Aging (Albany NY). 2017 Jul 30;9(7):1645-1646. (PMID: 28758893)
EMBO J. 2003 Oct 15;22(20):5491-500. (PMID: 14532121)
Anticancer Agents Med Chem. 2011 Nov;11(9):782-93. (PMID: 21707493)
Semin Immunol. 2011 Oct;23(5):368-78. (PMID: 21920773)
Leukemia. 2012 Jan;26(1):149-57. (PMID: 21799510)
Blood. 2011 Jun 2;117(22):5941-52. (PMID: 21527515)
Nat Cell Biol. 2016 Jan;18(1):21-32. (PMID: 26619147)
Leukemia. 2014 Oct;28(10):2066-74. (PMID: 24625551)
Oncology (Williston Park). 2005 Jul;19(8):983-4, 986. (PMID: 16131042)
Nature. 1996 Jun 27;381(6585):800-3. (PMID: 8657285)
Leukemia. 2011 Jun;25(6):1026-35. (PMID: 21468039)
Sci Rep. 2019 Apr 19;9(1):6304. (PMID: 31004086)
Curr Cancer Drug Targets. 2010 Jun;10(4):354-67. (PMID: 20370685)
Int J Colorectal Dis. 2012 Dec;27(12):1569-78. (PMID: 22684547)
Anal Biochem. 2005 Apr 1;339(1):129-36. (PMID: 15766719)
Expert Rev Hematol. 2014 Feb;7(1):113-25. (PMID: 24433088)
Can J Biochem Physiol. 1959 Aug;37(8):911-7. (PMID: 13671378)
Cancer Metastasis Rev. 2011 Dec;30(3-4):567-76. (PMID: 22005951)
Crit Rev Oncog. 2013;18(3):247-68. (PMID: 23510067)
J Cell Sci. 2011 Jul 1;124(Pt 13):2220-30. (PMID: 21652634)
Mol Cell. 2007 Aug 17;27(4):562-72. (PMID: 17707228)
Blood. 2008 Mar 1;111(5):2516-20. (PMID: 17975015)
Biochimie. 2010 Jun;92(6):707-15. (PMID: 20156522)
Genes Chromosomes Cancer. 2011 Oct;50(10):765-74. (PMID: 21961181)
Nucleic Acids Res. 2015 Nov 16;43(20):e133. (PMID: 26163063)
J Clin Oncol. 2012 Jun 1;30(16):1949-52. (PMID: 22547600)
Mol Cancer Res. 2017 Apr;15(4):405-417. (PMID: 28119431)
Cancer Res. 2016 Mar 1;76(5):1089-100. (PMID: 26833121)
Methods Mol Biol. 2019;1914:71-98. (PMID: 30729461)
Cancer Discov. 2015 Oct;5(10):1024-39. (PMID: 26382145)
Sci Rep. 2020 Oct 14;10(1):17319. (PMID: 33057033)
FASEB J. 2009 Mar;23(3):751-63. (PMID: 19028839)
J Biol Chem. 2007 Nov 23;282(47):34372-80. (PMID: 17895250)
Biochem Biophys Res Commun. 2008 Jun 20;371(1):159-62. (PMID: 18423379)
Cancer Biol Ther. 2011 Jan 15;11(2):138-49. (PMID: 21209555)
Nat Rev Cancer. 2015 Oct;15(10):593-607. (PMID: 26383138)
Leuk Lymphoma. 2015 Mar;56(3):602-7. (PMID: 24844357)
Prog Lipid Res. 2010 Oct;49(4):316-34. (PMID: 20193711)
Genes Cancer. 2012 Jan;3(1):23-36. (PMID: 22893788)
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):153-62. (PMID: 12531549)
Cancer Cell. 2008 Feb;13(2):167-80. (PMID: 18242516)
Am J Respir Cell Mol Biol. 2008 Jun;38(6):639-46. (PMID: 18192502)
J Pathol. 2013 Jan;229(1):36-48. (PMID: 22711564)
Trends Biochem Sci. 2011 Feb;36(2):97-107. (PMID: 20870412)
Nature. 2020 Jul;583(7818):699-710. (PMID: 32728249)
FASEB J. 2010 Aug;24(8):2727-38. (PMID: 20335228)
Leukemia. 2007 Mar;21(3):582-4. (PMID: 17215851)
Leukemia. 2012 Jul;26(7):1555-63. (PMID: 22285998)
Cancer Res. 2005 Aug 15;65(16):7478-84. (PMID: 16103102)
Mol Cancer Ther. 2014 Jan;13(1):154-64. (PMID: 24140934)
Mol Endocrinol. 1997 Jul;11(8):1103-13. (PMID: 9212058)
J Biol Chem. 2008 Dec 12;283(50):34994-5002. (PMID: 18852266)
Nature. 2012 Sep 6;489(7414):75-82. (PMID: 22955617)
Nature. 2012 Sep 6;489(7414):57-74. (PMID: 22955616)
Science. 2009 Sep 4;325(5945):1254-7. (PMID: 19729656)
Nat Cell Biol. 2004 Apr;6(4):308-18. (PMID: 15048125)
PLoS One. 2016 Jul 28;11(7):e0160344. (PMID: 27467586)
Blood. 2014 Sep 18;124(12):1915-25. (PMID: 25122609)
Cell Cycle. 2004 Sep;3(9):1133-7. (PMID: 15467447)
Mol Cell Biol. 1996 Aug;16(8):4024-34. (PMID: 8754800)
Subcell Biochem. 2008;49:487-522. (PMID: 18751924)
Cell Growth Differ. 2002 Feb;13(2):59-67. (PMID: 11864909)
Cell. 2012 Mar 30;149(1):22-35. (PMID: 22464321)
Leuk Lymphoma. 2016 Nov;57(11):2526-34. (PMID: 27243588)
Cold Spring Harb Perspect Med. 2014 Mar 01;4(3):. (PMID: 24591536)
JBMR Plus. 2019 Mar 15;3(3):e10183. (PMID: 30918921)
Int J Hematol. 2010 Sep;92(2):314-9. (PMID: 20694533)
Science. 2010 Jun 4;328(5983):1290-4. (PMID: 20522778)
Nat Rev Cancer. 2010 Jul;10(7):489-503. (PMID: 20555359)
Mol Genet Metab. 2018 Aug;124(4):278-286. (PMID: 29934064)
Cancer Sci. 2012 Aug;103(8):1538-45. (PMID: 22594559)
Endocrinology. 1990 May;126(5):2733-41. (PMID: 2184023)
Nat Commun. 2014 Sep 25;5:4806. (PMID: 25254944)
J Clin Oncol. 2009 Sep 1;27(25):4197-203. (PMID: 19636021)
Blood. 2012 Sep 20;120(12):2450-3. (PMID: 22806891)
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735. (PMID: 30462313)
Cancer Cell. 2013 Feb 11;23(2):200-14. (PMID: 23410974)
FEBS J. 2012 Aug;279(15):2610-23. (PMID: 22621751)
Blood. 2003 Jun 1;101(11):4569-75. (PMID: 12576322)
Int J Cancer. 2015 Jul 1;137(1):221-9. (PMID: 25429856)
Blood. 2005 Jul 1;106(1):125-34. (PMID: 15741222)
Br J Haematol. 2007 Sep;138(5):632-9. (PMID: 17686057)
Oncotarget. 2012 Aug;3(8):739-40. (PMID: 22964579)
J Hematol Oncol. 2018 Oct 4;11(1):123. (PMID: 30286780)
PLoS Biol. 2011 Apr;9(4):e1001046. (PMID: 21526222)
J Bone Miner Res. 1991 Mar;6(3):257-61. (PMID: 2035352)
Nat Methods. 2006 Jul;3(7):511-8. (PMID: 16791208)
Haematologica. 2018 Sep;103(9):e395-e399. (PMID: 29674496)
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16837-42. (PMID: 15550541)
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7859-64. (PMID: 10859351)
J Cell Biol. 2002 Sep 16;158(6):1039-49. (PMID: 12235122)
J Bone Miner Res. 1999 Jun;14(6):893-903. (PMID: 10352097)
Curr Mol Pharmacol. 2010 Jun;3(2):53-65. (PMID: 20302564)
Adv Exp Med Biol. 2010;688:141-55. (PMID: 20919652)
Immunity. 2002 May;16(5):733-44. (PMID: 12049724)
Nucleic Acids Res. 2017 Jan 4;45(D1):D658-D662. (PMID: 27789702)
معلومات مُعتمدة: R01 AR059679 (to DLG & GDR) United States AR NIAMS NIH HHS; I01 BX004514 United States BX BLRD VA; ( to PEA) The Interleukin Foundation , Denver CO; ACS-IRG # IRG-16-192-31 (to DNP) American Cancer Society; 2I01CX000623-05 (to GDR) VA Merit Review; R01 AR059679 United States AR NIAMS NIH HHS
فهرسة مساهمة: Keywords: GFI1; PP2A; S1P; SGPP1; c-Myc; multiple myeloma
تواريخ الأحداث: Date Created: 20220215 Latest Revision: 20220304
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8833953
DOI: 10.3390/cancers14030772
PMID: 35159039
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14030772